2022
Exploratory genomic analysis of high-grade neuroendocrine neoplasms across diverse primary sites.
Sun TY, Zhao L, Van Hummelen P, Martin B, Hornbacker K, Lee H, Xia LC, Padda SK, Ji HP, Kunz P. Exploratory genomic analysis of high-grade neuroendocrine neoplasms across diverse primary sites. Endocrine Related Cancer 2022, 29: 665-679. PMID: 36165930, PMCID: PMC10043760, DOI: 10.1530/erc-22-0015.Peer-Reviewed Original ResearchConceptsHigh-grade neuroendocrine neoplasmsDiverse primary sitesG3 NENNeuroendocrine neoplasmsPrimary siteHigh tumor mutation burdenExploratory genomic analysisTumor mutation burdenPoor survival outcomesMutations/MbDifferent primary sitesOrgan of originRare cancer typesSurvival outcomesWorse prognosisRare tumorCell cycling pathwaysMutation burdenTherapeutic implicationsClinical standpointSomatic copy number alterationsCopy number alterationsCancer typesNeoplasmsUpregulation of oncogenesMicroangiopathic Hemolytic Anemia Is a Late and Fatal Complication of Gastric Signet Ring Cell Carcinoma: A Systematic Review and Case-Control Study
Lam R, Tarangelo N, Wang R, Horibe M, Grimshaw AA, Jain D, Haffar S, Bazerbachi F, Kunz PL, Li DK. Microangiopathic Hemolytic Anemia Is a Late and Fatal Complication of Gastric Signet Ring Cell Carcinoma: A Systematic Review and Case-Control Study. The Oncologist 2022, 27: 751-759. PMID: 35589098, PMCID: PMC9438916, DOI: 10.1093/oncolo/oyac093.Peer-Reviewed Original ResearchMeSH KeywordsAnemia, HemolyticCarcinoma, Signet Ring CellCase-Control StudiesHumansPrognosisStomach NeoplasmsConceptsGastric signet ring cell carcinomaSignet ring cell carcinomaMicroangiopathic hemolytic anemiaHemolytic anemiaCell carcinomaMultivariable Cox proportional hazards regression modelingCox proportional hazards regression modelingSystematic reviewRare paraneoplastic syndromeStage-matched casesEnd Results (SEER) databaseLate-stage complicationsRisk of mortalityCase-control studyBone painParaneoplastic syndromeFatal complicationMedian survivalMetastatic diseaseOverall survivalLymph nodesIndex presentationPrognostic featuresResults databasePooled cohort
2021
177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial
Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, Mittra E, Wolin EM, Yao JC, Pavel ME, Grande E, Van Cutsem E, Seregni E, Duarte H, Gericke G, Bartalotta A, Mariani MF, Demange A, Mutevelic S, Krenning EP, investigators N. 177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. The Lancet Oncology 2021, 22: 1752-1763. PMID: 34793718, DOI: 10.1016/s1470-2045(21)00572-6.Peer-Reviewed Original ResearchConceptsMedian overall survivalMidgut neuroendocrine tumorsTreatment-related serious adverse eventsLong-term safety resultsFinal overall survivalPrespecified final analysisPhase 3 trialProgression-free survivalSerious adverse eventsOverall survivalLu-DOTATATE treatmentAdverse eventsNeuroendocrine tumorsLu-DOTATATESecondary endpointsLast patientMyelodysplastic syndromeSafety resultsInteractive web-based response systemControl groupAdvanced midgut neuroendocrine tumorsFinal overall survival analysisWeb-based response systemFinal analysisNETTER-1 trialExamination of factors associated with lymph node metastases in lung carcinoids: Results from a single institution retrospective cohort study
Pathipati MP, Yohannan TK, Tian L, Hornbacker K, Benson JA, Berry GJ, Lui NS, Kunz PL, Padda SK. Examination of factors associated with lymph node metastases in lung carcinoids: Results from a single institution retrospective cohort study. Lung Cancer 2021, 154: 186-194. PMID: 33551175, PMCID: PMC8026717, DOI: 10.1016/j.lungcan.2021.01.017.Peer-Reviewed Original ResearchConceptsLung neuroendocrine tumorsLymph nodesNeuroendocrine tumorsLung carcinoidsSSTR imagingLN metastasisAtypical carcinoidExact testSingle-institution retrospective cohort studyLymph node-positive diseaseAssociation of lymphPositive lymph nodesRetrospective cohort studyLymph node diseaseLymph node involvementNode-positive diseaseLymph node metastasisMultivariable logistic regressionFisher's exact testPre-operative workupN2 diseaseAdjuvant therapyLN involvementN1 diseaseNode involvement
2020
PAM staining intensity of primary neuroendocrine neoplasms is a potential prognostic biomarker
Horton TM, Sundaram V, Lee CH, Hornbacker K, Van Vleck A, Benjamin KN, Zemek A, Longacre TA, Kunz PL, Annes JP. PAM staining intensity of primary neuroendocrine neoplasms is a potential prognostic biomarker. Scientific Reports 2020, 10: 10943. PMID: 32616904, PMCID: PMC7331689, DOI: 10.1038/s41598-020-68071-6.Peer-Reviewed Original ResearchConceptsPrimary neuroendocrine neoplasmsNeuroendocrine neoplasmsPAM immunoreactivityPAM stainingStage-independent predictorUnpredictable clinical behaviorRisk of deathIndividual patient prognosisRare epithelial tumorsHigh-grade tumorsPotential prognostic biomarkerMedian timeSmall bowelAvailable biomarkersTumor sizeDisease stageClinical associationsGrade tumorsClinical behaviorPatient prognosisPrognostic biomarkerEpithelial tumorsTherapy selectionSurvival implicationsPatients
2019
Prognostic value of somatostatin receptor expressing tumor volume calculated from 68Ga-DOTATATE PET/CT in patients with well-differentiated neuroendocrine tumors
Toriihara A, Baratto L, Nobashi T, Park S, Hatami N, Davidzon G, Kunz PL, Iagaru A. Prognostic value of somatostatin receptor expressing tumor volume calculated from 68Ga-DOTATATE PET/CT in patients with well-differentiated neuroendocrine tumors. European Journal Of Nuclear Medicine And Molecular Imaging 2019, 46: 2244-2251. PMID: 31350603, DOI: 10.1007/s00259-019-04455-9.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overDisease ProgressionDisease-Free SurvivalFemaleHumansImage Processing, Computer-AssistedKaplan-Meier EstimateLiver NeoplasmsMaleMiddle AgedMultivariate AnalysisNeoplasm MetastasisNeuroendocrine TumorsOrganometallic CompoundsPositron Emission Tomography Computed TomographyPrognosisProgression-Free SurvivalProportional Hazards ModelsProspective StudiesReceptors, SomatostatinRetrospective StudiesConceptsProgression-free survivalProportional hazards modelPET/CTPrognostic valueTumor volumeNeuroendocrine tumorsTumor gradeSomatostatin receptorsKaplan-Meier survival analysisCox proportional hazards modelPositron emission tomography/Volume of interestMaximum standardized uptake valueMethodsNinety-two patientsWHO tumor gradeLog-rank testSomatostatin receptor expressionEmission tomography/Standardized uptake valueSignificant differencesVolumetric parametersPrimary endpointIndependent predictorsResultsUnivariate analysisTomography/
2015
Phase II pilot study of single-agent etirinotecan pegol (NKTR-102) in bevacizumab-resistant high grade glioma
Nagpal S, Recht CK, Bertrand S, Thomas RP, Ajlan A, Pena J, Gershon M, Coffey G, Kunz PL, Li G, Recht LD. Phase II pilot study of single-agent etirinotecan pegol (NKTR-102) in bevacizumab-resistant high grade glioma. Journal Of Neuro-Oncology 2015, 123: 277-282. PMID: 25935109, PMCID: PMC4452613, DOI: 10.1007/s11060-015-1795-0.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAngiogenesis InhibitorsAntineoplastic AgentsBevacizumabBrain NeoplasmsDrug Resistance, NeoplasmFemaleFollow-Up StudiesGliomaHeterocyclic Compounds, 4 or More RingsHumansMaleMiddle AgedNeoplasm GradingNeoplasm Recurrence, LocalPilot ProjectsPolyethylene GlycolsPrognosisProspective StudiesSurvival RateYoung AdultConceptsHigh-grade gliomasEtirinotecan pegolOverall survivalRANO criteriaPhase II pilot studyGrade 3 toxicityMedian overall survivalOpen-label trialFurther clinical investigationMedian KPSChemotherapy cyclesHematologic toxicityPrimary endpointSecondary endpointsPartial responseMedian agePatient agePoor prognosisHGG patientsTumor exposureClinical dataAnaplastic astrocytomaBevacizumabClinical investigationGrade gliomas
2013
Reassessment of the Current American Joint Committee on Cancer Staging System for Pancreatic Neuroendocrine Tumors
Qadan M, Ma Y, Visser BC, Kunz PL, Fisher GA, Norton JA, Poultsides GA. Reassessment of the Current American Joint Committee on Cancer Staging System for Pancreatic Neuroendocrine Tumors. Journal Of The American College Of Surgeons 2013, 218: 188-195. PMID: 24321190, DOI: 10.1016/j.jamcollsurg.2013.11.001.Peer-Reviewed Original ResearchConceptsPancreatic neuroendocrine tumorsAmerican Joint CommitteeStaging systemTNM systemOverall survivalSurgical resectionAJCC systemNeuroendocrine tumorsStage IIIJoint CommitteeCurative-intent surgical resectionEnd Results program dataStage IICurrent American Joint CommitteeCurrent AJCC staging systemCurrent AJCC systemDistant metastatic diseaseUnified staging systemDiscriminatory abilityCancer (AJCC) staging systemAJCC staging systemLymph node metastasisImproved discriminatory abilityNew TNM systemTNM subgroups
2012
Pancreatic Neuroendocrine Tumors: Radiographic Calcifications Correlate with Grade and Metastasis
Poultsides GA, Huang LC, Chen Y, Visser BC, Pai RK, Brooke Jeffrey R, Park WG, Chen AM, Kunz PL, Fisher GA, Norton JA. Pancreatic Neuroendocrine Tumors: Radiographic Calcifications Correlate with Grade and Metastasis. Annals Of Surgical Oncology 2012, 19: 2295-2303. PMID: 22396008, DOI: 10.1245/s10434-012-2305-7.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdenoma, Islet CellAdultAgedCalcinosisFemaleFollow-Up StudiesGastrinomaHumansInsulinomaLiver NeoplasmsLymphatic MetastasisMaleMiddle AgedNeoplasm StagingNeoplasms, Multiple PrimaryNeuroendocrine TumorsPancreatectomyPancreatic NeoplasmsPrognosisRetrospective StudiesStomach NeoplasmsTomography, X-Ray ComputedConceptsPancreatic neuroendocrine tumorsSynchronous liver metastasesLymph node metastasisLiver metastasesNode metastasisOverall survivalRadiographic calcificationsHigh-grade pancreatic neuroendocrine tumorsComputed tomography correlateIntermediate tumor gradeRegional lymph nodesPreoperative computed tomographyPresence of calcificationCurative intentFormal pancreatectomyMethodsFrom 1998Surgical resectionIndependent predictorsLymph nodesPrognostic significanceCalcified tumorClinicopathologic variablesNeuroendocrine tumorsPrimary tumorTumor grade
2010
Expression of p16INK4A but not hypoxia markers or poly adenosine diphosphate‐ribose polymerase is associated with improved survival in patients with pancreatic adenocarcinoma
Chang DT, Chapman CH, Norton JA, Visser B, Fisher GA, Kunz P, Ford JM, Koong AC, Pai RK. Expression of p16INK4A but not hypoxia markers or poly adenosine diphosphate‐ribose polymerase is associated with improved survival in patients with pancreatic adenocarcinoma. Cancer 2010, 116: 5179-5187. PMID: 20665497, DOI: 10.1002/cncr.25481.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overAntigens, NeoplasmBiomarkers, TumorCarbonic Anhydrase IXCarbonic AnhydrasesCell HypoxiaCyclin-Dependent Kinase Inhibitor p16Disease-Free SurvivalFemaleHumansImmunohistochemistryMaleMiddle AgedPancreatic NeoplasmsPoly(ADP-ribose) PolymerasesPrognosisProto-Oncogene ProteinsProto-Oncogene Proteins p21(ras)Ras ProteinsTetrahydrofolate DehydrogenaseTissue Array AnalysisConceptsProgression-free survivalOverall survivalPoly adenosine diphosphate-ribose polymerasePancreatic adenocarcinomaImproved OSImmunohistochemical expressionHypoxia markersImproved overall survivalCyclin-dependent kinase inhibitor 2AExpression of p16INK4aCarbonic anhydrase IXAdjuvant chemotherapyCurative resectionMedian survivalImproved survivalMargin statusClinical outcomesPrimary tumorPancreatic cancerUnivariate analysisSurgical specimensImmunohistochemical stainingTissue microarrayPositive stainingPatientsComparison of intensity‐modulated radiotherapy and 3‐dimensional conformal radiotherapy as adjuvant therapy for gastric cancer
Minn AY, Hsu A, La T, Kunz P, Fisher GA, Ford JM, Norton JA, Visser B, Goodman KA, Koong AC, Chang DT. Comparison of intensity‐modulated radiotherapy and 3‐dimensional conformal radiotherapy as adjuvant therapy for gastric cancer. Cancer 2010, 116: 3943-3952. PMID: 20564136, DOI: 10.1002/cncr.25246.Peer-Reviewed Original ResearchConceptsIntensity-modulated radiotherapyCRT groupGastric cancerConformal radiotherapyIMRT patientsAcute gastrointestinal toxicityMedian radiation doseMedian serum creatinineGastroesophageal junction cancerOverall survival rateConcurrent chemotherapyKidney V20Liver V30Median liverRecent creatinineAdjuvant chemoradiotherapyAdjuvant therapyGastrointestinal toxicityIMRT groupLocoregional failurePostoperative chemoradiotherapyJunction cancerRenal functionSerum creatinineTreatment breaks